CAR-T Cell Therapy for Relapsed, Refractory Mantle Cell Lymphoma Fills Unmet Need
Treatment with CAR-T cell therapy Breyanzi (lisocabtagene maraleucel; liso-cel) now opens up options for patients with relapsed or refractory mantle cell lymphoma (MCL), following the Food and Drug Administration’s (FDA) approval in late May. Of note, …